The Food and Drug Administration (FDA) has approved Itovebi (inavolisib) with Ibrance (palbociclib) and Faslodex (fulvestrant) for certain patients with advanced or metastatic breast cancer. For a ...
Regulatory officials have identified 82 cases worldwide from the FDA Adverse Event Reporting System of anaphylaxis associated with the use of Coxapone and the generic Glatopa that have resulted in ...
The Susvimo implant — the size of a grain of rice — can be refilled by needle every six months. Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled ...
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness – Susvimo is the first and only continuous delivery ...
--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) ...
Genentech Inc. is seeking to challenge a federal health agency’s decision to allow certain clinics in Nevada that treat sexually transmitted diseases to participate in a drug discount program. The ...
The addition of inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant (Faslodex) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) ...
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. * ...
Genentech is the latest drugmaker to sue the federal government over STD clinics it says are wrongfully receiving discounts through the federal 340B program. … ...
The likes of gene therapy (for Duchenne Muscular Dystrophy, “DMD”), Elevidys, Lymphoma meds Columvi and Itovebi, and Piasky, developed to treat paroxysmal nocturnal haemoglobinuria (“PNH ...
An updated analysis of a phase III trial showed that the PI3K inhibitor inavolisib (Itovebi), in combination with palbociclib (Ibrance) and fulvestrant, significantly improved overall survival in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results